盘点:近期前列腺癌相关分子机制研究进展(二)

2020-12-31 AlexYang MedSci原创

【1】Cell Death & Disease:MiRNA-671-5p通过靶向NFIA/CRYAB途径促进前列腺癌的发展和转移

【1】Cell Death & Disease:MiRNA-671-5p通过靶向NFIA/CRYAB途径促进前列腺癌的发展和转移

前列腺癌(PCa)是男性恶性肿瘤致死的第二位死因,转移是PCa患者死亡的主要原因。微RNAs(miRNAs)在肿瘤的发展和转移中起着重要的调控作用。

最近,有研究人员通过生物信息学分析发现了13个与PCa转移相关的miRNAs。此外,他们还发现miR-671-5p在转移性PCa组织中增加,其高表达预示着PCa的不良预后。MiR-671-5p可以促进PCa细胞在体外和体内的增殖、迁移和侵袭。研究人员还证实了miR-671-5p能够直接与NFIA mRNA的3'非翻译区结合,NFIA直接与CRYAB的启动子结合。NFIA和CRYAB的高表达与PCa患者的晚期临床病理特征和转移状态呈负相关。

最后,研究人员指出,他们的研究表明了miR-671-5p能够通过抑制NFIA/CRYAB途径促进PCa的发展和转移。

【2】Oncogene:Myc在调节前列腺癌脂肪酸合成中的新型代谢功能

部分人类前列腺癌表现出脂肪酸的从头合成增加,但这种代谢异常的分子驱动因素仍不清楚。

最近,有研究人员揭示了c-Myc(Myc)在调节脂肪酸合成中的一种新的代谢功能。研究人员通过以下方法调查了Myc在调节脂肪酸合成中的作用:(a)前列腺癌基因组图谱(TCGA)数据集的查询,(b)染色质免疫沉淀,(c)利用小鼠模型和人类样本测定脂肪酸合成酶的表达和靶向代谢组学。研究结果表明,在前列腺癌TCGA数据集中,MYC的表达与ACLY、ACC1和FASN等关键脂肪酸合成基因的表达呈正相关。染色质免疫共沉淀显示Myc能够结合ACLY、ACC1和FASN的启动子。Hi-Myc转基因小鼠中前列腺特异性过度表达Myc能够导致肿瘤病灶中ACLY、ACC1和FASN蛋白过度表达,并增加循环总游离脂肪酸水平。靶向代谢组学证实了与相应的对照组相比,Hi-Myc小鼠和人类受试者血浆中循环单个脂肪酸水平增加。免疫组化也揭示了人前列腺癌样本中Myc与ACC1的表达显著呈正相关。

最后,研究人员指出,Myc调控的脂肪酸合成是治疗和/或预防前列腺癌的有效靶点。

【3】Oncogene:Plectin是前列腺癌生长和转移的调节因子

前列腺癌每年造成3万多美国人死亡,主要归因于无法治愈的转移性疾病。

最近,有研究人员阐释了与良性前列腺组织相比,高水平的plectin与局部和转移性人类前列腺癌有关。敲除plectin能够抑制前列腺癌细胞在体外的生长和克隆形成,以及体内前列腺癌异种移植的生长。Plectin敲除能够进一步干扰通过体外迁移、入侵和伤口愈合评估的侵袭性和侵入性细胞行为。一致地,plectin基因敲除细胞的远处部位转移定植受损,包括肝、肺、肾、骨和泌尿生殖系统。Plectin基因敲除抑制了每个器官的转移数量,并降低了整体转移负担。为了深入了解plectin在前列腺癌生长和转移中的作用,研究人员对前列腺癌plectin敲除异种移植组织进行了蛋白质组学分析。基因集富集分析表明,与细胞外基质和层粘连蛋白相互作用有关的蛋白质水平增加,而调节氨基酸代谢、细胞骨架蛋白和细胞应激反应蛋白质水平下降。

最后,研究人员指出,他们的研究发现阐释了plectin是前列腺癌细胞生长和转移的重要调节因子。

【4】Brit J Cancer:miR-199b-5p-DDR1-ERK信号轴通过抑制上皮-间质转化抑制前列腺癌转移

转移性前列腺癌(PCa)仍旧需要迫切的调查其潜在机制和探索新的疗法。miR-199b-5p在各种人类癌症中被认为时肿瘤抑制子,但miR-199b-5p在PCa中的临床意义和作用仍不清楚。

研究结果表明,与正常前列腺组织、局部疾病、弱转移和雄激素依赖性PCa细胞以及正常前列腺上皮细胞相比,miR-199b-5p在转移性PCa组织和细胞中显著下调。另外,miR-199b-5p在体外能大幅抑制PCa细胞的增殖、迁移和侵袭;且在体内能够抑制异种移植肿瘤的生长和转移。机理研究结果表明,miR-199b-5p可以通过直接靶向其3'-UTR,抑制盘状结构域受体酪氨酸激酶1(DDR1)的表达,从而阻碍上皮-间质转化(EMT)相关性状,而这些性状是由DDR1激活的ERK信号通路诱导的。此外,miR-199b-5p低水平表达的PCa患者的总生存期明显短于高水平miR-199b-5p患者,表明miR-199b-5p的缺失与PCa患者的不良预后有关。更多的时,DDR1在PCa中上调,与高Gleason评分、晚期病理分期、肿瘤转移和较短的总生存显著相关。

最后,研究人员指出,他们的研究首次提供了miR-199b-5p在PCa的侵袭和转移中具有抑瘤功能的证据,支持基于miR-199b-5p的PCa转移治疗方法的转化利用。同时,他们发现的miR-199b-5p-DDR1-ERK信号轴也代表了PCa转移中EMT的一种新的调控机制。

【5】Oncogene:前列腺癌中FRMD6具有抑制肿瘤的功能

现有的前列腺癌(PC)预后工具不是最优的,但可能通过更好地了解驱动肿瘤侵袭性的基因来改善。

最近,有研究人员鉴定了FRMD6(包含FERM结构与的蛋白6)是PC中一个异常超甲基化和显著下调的基因。在两个大型PC患者队列中,FRMD6的低表达与术后生化复发相关。在PC细胞系的过表达和CRISPR/Cas9敲除实验中,FRMD6能够抑制生存力、增殖、细胞周期进展、克隆形成、3D球体生长和肿瘤异种移植生长。转录组、蛋白质组和磷酸蛋白质组分析显示,FRMD6敲除后Hippo/YAP和c-MYC信号富集。连通图分析和药物再利用实验确定了pyroxamide可作为FRMD6缺失PC细胞的一种新的潜在疗法。最后,研究人员在ROSA26小鼠前列腺中建立了正交的Frmd6和Pten,或仅Pten(对照)敲除。12周后,Frmd6/Pten双基因敲除表现出高级别前列腺上皮内瘤变(HG-PIN)和过度增殖,而Pten单基因敲除仅出现常规PIN病变,并表现出较低程度的增殖。

最后,研究人员指出,他们的研究确定了FRMD6为PC中的新肿瘤抑制基因和预后生物标志物候选基因。

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2056212, encodeId=812320562121e, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Oct 19 17:18:57 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953542, encodeId=6cf8195354225, content=<a href='/topic/show?id=b3ec60803a2' target=_blank style='color:#2F92EE;'>#期前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60803, encryptionId=b3ec60803a2, topicName=期前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4723380, createdName=yangcx0915, createdTime=Sat Feb 27 03:18:57 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913432, encodeId=f7df913432da, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/x6iajibNtNZjFCmSurvMHwYYSgjFcFzribMrPtZpvsEWlsRRs9e16AZ3X1NYOJZ29Cjsib0Of5ic63hyyfKYG20GYug/132, createdBy=d48a5329766, createdName=Wenking, createdTime=Sun Jan 03 23:19:57 CST 2021, time=2021-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913124, encodeId=05d29131245c, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sat Jan 02 19:10:14 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1381309, encodeId=d95413813090d, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sat Jan 02 06:18:57 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039365, encodeId=f341103936522, content=机制研究离临床仍然有距离,不过与临床结合思考,仍然有帮助的,不能仅仅是纯临床思维,转化思维同样重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Thu Dec 31 18:18:57 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040918, encodeId=a9ce104091822, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Dec 31 18:18:57 CST 2020, time=2020-12-31, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2056212, encodeId=812320562121e, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Oct 19 17:18:57 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953542, encodeId=6cf8195354225, content=<a href='/topic/show?id=b3ec60803a2' target=_blank style='color:#2F92EE;'>#期前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60803, encryptionId=b3ec60803a2, topicName=期前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4723380, createdName=yangcx0915, createdTime=Sat Feb 27 03:18:57 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913432, encodeId=f7df913432da, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/x6iajibNtNZjFCmSurvMHwYYSgjFcFzribMrPtZpvsEWlsRRs9e16AZ3X1NYOJZ29Cjsib0Of5ic63hyyfKYG20GYug/132, createdBy=d48a5329766, createdName=Wenking, createdTime=Sun Jan 03 23:19:57 CST 2021, time=2021-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913124, encodeId=05d29131245c, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sat Jan 02 19:10:14 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1381309, encodeId=d95413813090d, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sat Jan 02 06:18:57 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039365, encodeId=f341103936522, content=机制研究离临床仍然有距离,不过与临床结合思考,仍然有帮助的,不能仅仅是纯临床思维,转化思维同样重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Thu Dec 31 18:18:57 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040918, encodeId=a9ce104091822, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Dec 31 18:18:57 CST 2020, time=2020-12-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2056212, encodeId=812320562121e, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Oct 19 17:18:57 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953542, encodeId=6cf8195354225, content=<a href='/topic/show?id=b3ec60803a2' target=_blank style='color:#2F92EE;'>#期前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60803, encryptionId=b3ec60803a2, topicName=期前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4723380, createdName=yangcx0915, createdTime=Sat Feb 27 03:18:57 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913432, encodeId=f7df913432da, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/x6iajibNtNZjFCmSurvMHwYYSgjFcFzribMrPtZpvsEWlsRRs9e16AZ3X1NYOJZ29Cjsib0Of5ic63hyyfKYG20GYug/132, createdBy=d48a5329766, createdName=Wenking, createdTime=Sun Jan 03 23:19:57 CST 2021, time=2021-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913124, encodeId=05d29131245c, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sat Jan 02 19:10:14 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1381309, encodeId=d95413813090d, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sat Jan 02 06:18:57 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039365, encodeId=f341103936522, content=机制研究离临床仍然有距离,不过与临床结合思考,仍然有帮助的,不能仅仅是纯临床思维,转化思维同样重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Thu Dec 31 18:18:57 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040918, encodeId=a9ce104091822, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Dec 31 18:18:57 CST 2020, time=2020-12-31, status=1, ipAttribution=)]
    2021-01-03 Wenking

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2056212, encodeId=812320562121e, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Oct 19 17:18:57 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953542, encodeId=6cf8195354225, content=<a href='/topic/show?id=b3ec60803a2' target=_blank style='color:#2F92EE;'>#期前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60803, encryptionId=b3ec60803a2, topicName=期前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4723380, createdName=yangcx0915, createdTime=Sat Feb 27 03:18:57 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913432, encodeId=f7df913432da, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/x6iajibNtNZjFCmSurvMHwYYSgjFcFzribMrPtZpvsEWlsRRs9e16AZ3X1NYOJZ29Cjsib0Of5ic63hyyfKYG20GYug/132, createdBy=d48a5329766, createdName=Wenking, createdTime=Sun Jan 03 23:19:57 CST 2021, time=2021-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913124, encodeId=05d29131245c, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sat Jan 02 19:10:14 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1381309, encodeId=d95413813090d, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sat Jan 02 06:18:57 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039365, encodeId=f341103936522, content=机制研究离临床仍然有距离,不过与临床结合思考,仍然有帮助的,不能仅仅是纯临床思维,转化思维同样重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Thu Dec 31 18:18:57 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040918, encodeId=a9ce104091822, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Dec 31 18:18:57 CST 2020, time=2020-12-31, status=1, ipAttribution=)]
    2021-01-02 ms3000000449926787

    学习了!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2056212, encodeId=812320562121e, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Oct 19 17:18:57 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953542, encodeId=6cf8195354225, content=<a href='/topic/show?id=b3ec60803a2' target=_blank style='color:#2F92EE;'>#期前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60803, encryptionId=b3ec60803a2, topicName=期前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4723380, createdName=yangcx0915, createdTime=Sat Feb 27 03:18:57 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913432, encodeId=f7df913432da, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/x6iajibNtNZjFCmSurvMHwYYSgjFcFzribMrPtZpvsEWlsRRs9e16AZ3X1NYOJZ29Cjsib0Of5ic63hyyfKYG20GYug/132, createdBy=d48a5329766, createdName=Wenking, createdTime=Sun Jan 03 23:19:57 CST 2021, time=2021-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913124, encodeId=05d29131245c, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sat Jan 02 19:10:14 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1381309, encodeId=d95413813090d, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sat Jan 02 06:18:57 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039365, encodeId=f341103936522, content=机制研究离临床仍然有距离,不过与临床结合思考,仍然有帮助的,不能仅仅是纯临床思维,转化思维同样重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Thu Dec 31 18:18:57 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040918, encodeId=a9ce104091822, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Dec 31 18:18:57 CST 2020, time=2020-12-31, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2056212, encodeId=812320562121e, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Oct 19 17:18:57 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953542, encodeId=6cf8195354225, content=<a href='/topic/show?id=b3ec60803a2' target=_blank style='color:#2F92EE;'>#期前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60803, encryptionId=b3ec60803a2, topicName=期前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4723380, createdName=yangcx0915, createdTime=Sat Feb 27 03:18:57 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913432, encodeId=f7df913432da, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/x6iajibNtNZjFCmSurvMHwYYSgjFcFzribMrPtZpvsEWlsRRs9e16AZ3X1NYOJZ29Cjsib0Of5ic63hyyfKYG20GYug/132, createdBy=d48a5329766, createdName=Wenking, createdTime=Sun Jan 03 23:19:57 CST 2021, time=2021-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913124, encodeId=05d29131245c, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sat Jan 02 19:10:14 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1381309, encodeId=d95413813090d, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sat Jan 02 06:18:57 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039365, encodeId=f341103936522, content=机制研究离临床仍然有距离,不过与临床结合思考,仍然有帮助的,不能仅仅是纯临床思维,转化思维同样重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Thu Dec 31 18:18:57 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040918, encodeId=a9ce104091822, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Dec 31 18:18:57 CST 2020, time=2020-12-31, status=1, ipAttribution=)]
    2020-12-31 肿肿

    机制研究离临床仍然有距离,不过与临床结合思考,仍然有帮助的,不能仅仅是纯临床思维,转化思维同样重要

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2056212, encodeId=812320562121e, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Oct 19 17:18:57 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953542, encodeId=6cf8195354225, content=<a href='/topic/show?id=b3ec60803a2' target=_blank style='color:#2F92EE;'>#期前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60803, encryptionId=b3ec60803a2, topicName=期前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4723380, createdName=yangcx0915, createdTime=Sat Feb 27 03:18:57 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913432, encodeId=f7df913432da, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/x6iajibNtNZjFCmSurvMHwYYSgjFcFzribMrPtZpvsEWlsRRs9e16AZ3X1NYOJZ29Cjsib0Of5ic63hyyfKYG20GYug/132, createdBy=d48a5329766, createdName=Wenking, createdTime=Sun Jan 03 23:19:57 CST 2021, time=2021-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913124, encodeId=05d29131245c, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sat Jan 02 19:10:14 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1381309, encodeId=d95413813090d, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sat Jan 02 06:18:57 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039365, encodeId=f341103936522, content=机制研究离临床仍然有距离,不过与临床结合思考,仍然有帮助的,不能仅仅是纯临床思维,转化思维同样重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Thu Dec 31 18:18:57 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040918, encodeId=a9ce104091822, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Dec 31 18:18:57 CST 2020, time=2020-12-31, status=1, ipAttribution=)]
    2020-12-31 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

Brit J Cancer:PTN可作为前列腺癌转移的生物标志物

从惰性前列腺癌(PC)中区分临床显著前列腺癌是一个重大的临床挑战。

Br J Cancer:LIMK2介导的SPOP磷酸化降解促进去势抵抗性前列腺癌的发生发展

前列腺癌(PCa)目前仍是泌尿外科癌症中最普遍的类型,在美国,其在男性癌症相关死亡中排名第二。2020年美国约有191,930例新病例和33,330例预测死亡病例。尽管雄激素剥夺疗法可以有效治疗该疾病

Eur Urol:前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描成像对前列腺癌是否划算?

在将前列腺特异性膜抗原(PSMA)正电子发射断层扫描/计算机断层扫描(PET/CT)纳入常规护理之前,评估其效益是重要的。最近,有研究人员确定了PSMA-PET/CT与常规成像相比的效益情况。

Oncogene:钙调素促进前列腺癌休眠

前列腺癌是男性死亡的主要原因之一。前列腺癌患者死亡的主要原因可归结为疾病的转移扩散或初始治疗后的肿瘤复发。前列腺肿瘤发展成为局部或远处部位可见肿瘤之前,长期处于不能检测到或休眠状态。然而,休眠的分子机

Eur Urol:前列腺根治性切除术后局部复发患者的抢救手术

自前列腺特异性膜抗原(PSMA)正电子发射断层扫描(PET)成像技术问世以来,人们可以准确划分根治性前列腺切除术(RP)后的孤立性局部复发。

盘点:近期前列腺癌与治疗进展(二)

【1】JAMA Netw Open:使用雄激素受体抑制剂治疗前列腺癌男性的跌倒和骨折风险